Follow the people · Insider
Christopher R. Cline
Christopher R. Cline files insider transactions with the SEC as a chief financial officer of Travere Therapeutics (TVTX). We hold 8 disclosed purchases and sales filed since 1 September 2022, 1 of them in the last 90 days.
- Files forTVTX
- Disclosed buys and sells8 in all, 1 in the last 90 days
- Last disclosure3 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 September 2022 — 2 September 2026Chief Financial Officer · Travere Therapeutics (TVTX)54 Form 4 lines · source: SEC Form 4
Everything they disclosed
54 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 642 shares of Travere TherapeuticsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- exercised options over 4,250 shares of Travere TherapeuticsSEC Form 46 May 2026Common Stock · traded 4 May 2026 · filed 6 May 2026
- ▼ sold on the open market 2,181 shares of Travere TherapeuticsSEC Form 46 May 2026Common Stock · traded 5 May 2026 · filed 6 May 2026
- ▼ sold on the open market 310 shares of Travere TherapeuticsSEC Form 46 May 2026Common Stock · traded 6 May 2026 · filed 6 May 2026
- was granted 8,500 shares of Travere Therapeutics (a derivative holding)SEC Form 46 May 2026Performance-based restricted stock units · traded 4 May 2026 · filed 6 May 2026
- exercised options over 4,250 shares of Travere Therapeutics (a derivative holding)SEC Form 46 May 2026Performance-based restricted stock units · traded 4 May 2026 · filed 6 May 2026
- was granted 14,000 shares of Travere TherapeuticsSEC Form 415 April 2026Common Stock · traded 13 April 2026 · filed 15 April 2026
- ▼ sold on the open market 65 shares of Travere TherapeuticsSEC Form 415 April 2026Common Stock · traded 13 April 2026 · filed 15 April 2026
- ▼ sold on the open market 9 shares of Travere TherapeuticsSEC Form 415 April 2026Common Stock · traded 14 April 2026 · filed 15 April 2026
- ▼ sold on the open market 7,239 shares of Travere TherapeuticsSEC Form 415 April 2026Common Stock · traded 14 April 2026 · filed 15 April 2026
- ▼ sold on the open market 1,014 shares of Travere TherapeuticsSEC Form 415 April 2026Common Stock · traded 15 April 2026 · filed 15 April 2026
- ▼ sold on the open market 1,635 shares of Travere TherapeuticsSEC Form 45 February 2026Common Stock · traded 4 February 2026 · filed 5 February 2026
- ▼ sold on the open market 110 shares of Travere TherapeuticsSEC Form 45 February 2026Common Stock · traded 4 February 2026 · filed 5 February 2026
- ▼ sold on the open market 1,635 shares of Travere TherapeuticsSEC Form 45 February 2026Common Stock · traded 4 February 2026 · filed 5 February 2026
- ▼ sold on the open market 110 shares of Travere TherapeuticsSEC Form 45 February 2026Common Stock · traded 4 February 2026 · filed 5 February 2026
- was granted 28,130 shares of Travere TherapeuticsSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- ▼ sold on the open market 7,242 shares of Travere TherapeuticsSEC Form 43 February 2026Common Stock · traded 3 February 2026 · filed 3 February 2026
- was granted 75,000 shares of Travere Therapeutics (a derivative holding)SEC Form 43 February 2026Employee stock option (right to buy) · traded 31 January 2026 · filed 3 February 2026
- was granted 75,000 shares of Travere Therapeutics (a derivative holding)SEC Form 43 February 2026Employee stock option (right to buy) · traded 31 January 2026 · filed 3 February 2026
- was granted 28,130 shares of Travere TherapeuticsSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- ▼ sold on the open market 7,242 shares of Travere TherapeuticsSEC Form 43 February 2026Common Stock · traded 3 February 2026 · filed 3 February 2026
- exercised options over 20,000 shares of Travere Therapeutics (a derivative holding)SEC Form 43 December 2025Employee stock option (right to buy) · traded 1 December 2025 · filed 3 December 2025
- exercised options over 20,000 shares of Travere TherapeuticsSEC Form 43 December 2025Common Stock · traded 1 December 2025 · filed 3 December 2025
- ▼ sold on the open market 20,000 shares of Travere TherapeuticsSEC Form 43 December 2025Common Stock · traded 1 December 2025 · filed 3 December 2025
- ▼ sold on the open market 454 shares of Travere TherapeuticsSEC Form 45 September 2025Common Stock · traded 3 September 2025 · filed 5 September 2025
- ▼ sold on the open market 119 shares of Travere TherapeuticsSEC Form 45 September 2025Common Stock · traded 4 September 2025 · filed 5 September 2025
- ▼ sold on the open market 470 shares of Travere TherapeuticsSEC Form 428 August 2025Common Stock · traded 27 August 2025 · filed 28 August 2025
- exercised options over 4,920 shares of Travere Therapeutics (a derivative holding)SEC Form 45 May 2025Performance-based restricted stock units · traded 2 May 2025 · filed 5 May 2025
- exercised options over 4,920 shares of Travere TherapeuticsSEC Form 45 May 2025Common Stock · traded 2 May 2025 · filed 5 May 2025
- ▼ sold on the open market 1,784 shares of Travere TherapeuticsSEC Form 45 May 2025Common Stock · traded 5 May 2025 · filed 5 May 2025
- ▼ sold on the open market 48 shares of Travere TherapeuticsSEC Form 414 April 2025Common Stock · traded 11 April 2025 · filed 14 April 2025
- was granted 58,000 shares of Travere Therapeutics (a derivative holding)SEC Form 44 February 2025Employee stock option (right to buy) · traded 31 January 2025 · filed 4 February 2025
- was granted 21,500 shares of Travere TherapeuticsSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- ▼ sold on the open market 5,192 shares of Travere TherapeuticsSEC Form 44 February 2025Common Stock · traded 3 February 2025 · filed 4 February 2025
- ▼ sold on the open market 865 shares of Travere TherapeuticsSEC Form 423 January 2025Common Stock · traded 22 January 2025 · filed 23 January 2025
- was granted 6,750 shares of Travere TherapeuticsSEC Form 49 September 2024Common Stock · traded 5 September 2024 · filed 9 September 2024
- ▼ sold on the open market 2,490 shares of Travere TherapeuticsSEC Form 49 September 2024Common Stock · traded 9 September 2024 · filed 9 September 2024
- ▼ sold on the open market 514 shares of Travere TherapeuticsSEC Form 45 September 2024Common Stock · traded 4 September 2024 · filed 5 September 2024
- ▼ sold on the open market 54 shares of Travere TherapeuticsSEC Form 412 April 2024Common Stock · traded 11 April 2024 · filed 12 April 2024
- was granted 65,000 shares of Travere Therapeutics (a derivative holding)SEC Form 42 February 2024Employee stock option (right to buy) · traded 31 January 2024 · filed 2 February 2024
- was granted 25,000 shares of Travere TherapeuticsSEC Form 42 February 2024Common Stock · traded 31 January 2024 · filed 2 February 2024
- ▼ sold on the open market 3,818 shares of Travere TherapeuticsSEC Form 42 February 2024Common Stock · traded 1 February 2024 · filed 2 February 2024
- ▼ sold on the open market 853 shares of Travere TherapeuticsSEC Form 425 January 2024Common Stock · traded 23 January 2024 · filed 25 January 2024
- ▼ sold on the open market 457 shares of Travere TherapeuticsSEC Form 45 September 2023Common Stock · traded 5 September 2023 · filed 5 September 2023
- ▼ sold on the open market 455 shares of Travere TherapeuticsSEC Form 412 May 2023Common Stock · traded 10 May 2023 · filed 12 May 2023
- ▼ sold on the open market 47 shares of Travere TherapeuticsSEC Form 413 April 2023Common Stock · traded 11 April 2023 · filed 13 April 2023
- was granted 54,500 shares of Travere Therapeutics (a derivative holding)SEC Form 42 February 2023Employee stock option (right to buy) · traded 31 January 2023 · filed 2 February 2023
- was granted 6,750 shares of Travere Therapeutics (a derivative holding)SEC Form 42 February 2023Performance-based restricted stock units · traded 31 January 2023 · filed 2 February 2023
- was granted 20,250 shares of Travere TherapeuticsSEC Form 42 February 2023Common Stock · traded 31 January 2023 · filed 2 February 2023
- ▼ sold on the open market 1,588 shares of Travere TherapeuticsSEC Form 42 February 2023Common Stock · traded 1 February 2023 · filed 2 February 2023
- ▼ sold on the open market 852 shares of Travere TherapeuticsSEC Form 426 January 2023Common Stock · traded 24 January 2023 · filed 26 January 2023
- was granted 48,000 shares of Travere Therapeutics (a derivative holding)SEC Form 41 September 2022Employee Stock option (right to buy) · traded 1 September 2022 · filed 1 September 2022
- was granted 9,840 shares of Travere Therapeutics (a derivative holding)SEC Form 41 September 2022Performance-based restricted stock units · traded 1 September 2022 · filed 1 September 2022
- was granted 5,000 shares of Travere TherapeuticsSEC Form 41 September 2022Common Stock · traded 1 September 2022 · filed 1 September 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.